Seres Therapeutics (Seres Therapeutics) Days Sales Outstanding : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Days Sales Outstanding?

Seres Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was $0.0 Mil. Seres Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.0 Mil.

The historical rank and industry rank for Seres Therapeutics's Days Sales Outstanding or its related term are showing as below:

During the past 12 years, Seres Therapeutics's highest Days Sales Outstanding was 61.38. The lowest was 18.88. And the median was 23.64.

MCRB's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.43
* Ranked among companies with meaningful Days Sales Outstanding only.

Seres Therapeutics's Days Sales Outstanding stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Seres Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Seres Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seres Therapeutics Days Sales Outstanding Chart

Seres Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

18.88

61.38

23.64

Seres Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Seres Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Seres Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Days Sales Outstanding falls into.

Seres Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Seres Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	126.325	*	365
=	0					/	126.325	*	365
=	0.00

Seres Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Seres Therapeutics (NAS:MCRB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Seres Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Seres Therapeutics (Seres Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (NAS:MCRB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

1S9:Germany

Address

200 Sidney Street, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.serestherapeutics.com

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Executives

Paula Cloghessy	officer: See Remarks	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Matthew R. Henn	officer: Chief Scientific Officer	C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Eric D. Shaff	officer: CFO and EVP	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Thomas Desrosier	officer: See Remarks	65 HAYDEN AVENUE, LEXINGTON MA 02421
Moltke Lisa Von	officer: See Remarks	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Teresa L. Young	officer: See Remarks	C/O SERES THERAPEUTICS, INC., SUITE 1750, HOUSTON TX 77098
David S. Ege	officer: See Remarks	C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
David Arkowitz	officer: Chief Financial Officer	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Claire Fraser	director	C/O BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07465
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv-rx, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142